Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Ισραήλ - Εβραϊκά - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - אבקה להכנת תרחיף - cefalexin as monohydrate 250 mg / 5 ml - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

Ισραήλ - Εβραϊκά - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 250 mg - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

Ισραήλ - Εβραϊκά - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 500 mg - cefalexin - cefalexin - treatment of infections caused by cephalexin susceptible microorganisms.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - moxifloxacin - תמיסה לאינפוזיה - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Ισραήλ - Εβραϊκά - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated mumps virus 10^3.7 ccid50; live attenuated rubella virus 10^3.0 ccid50; live attenuated measles virus 10^3.0 ccid50 - rubella, combinations with mumps, live attenuated - rubella, combinations with mumps, live attenuated - priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.

Ισραήλ - Εβραϊκά - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.